类风湿关节炎缓解后按基线TNF-α调整英夫利西单抗剂量策略的持续停药研究:RRRR随机对照试验
RRRR多中心随机对照试验纳入337例甲氨蝶呤应答不足的英夫利西单抗初治类风湿关节炎患者,比较按基线血清TNF-α调整英夫利西单抗剂量的程序化策略与标准3 mg/kg方案。第54周两组达到SDAI≤3.3缓解的比例分别为39.4%与32.3%,第106周持续停药率分别为23.5%与21.6%,差异无统计学意义。程序化策略未显著提高停药1年后的持续缓解率,基线SDAI<26.0为成功持续停药的显著预测因素。
要点
- 程序化按基线TNF-α调整英夫利西单抗剂量未显著提高第106周持续停药率。
- 第54周SDAI≤3.3缓解率程序化组39.4%、标准组32.3%。
- 基线SDAI<26.0是第106周成功持续停药的显著预测因素。
核心结论
- 程序化治疗策略未在统计学上提高英夫利西单抗停药1年后的持续缓解率。
研究设计与样本
- 多中心随机对照试验纳入337例甲氨蝶呤应答不足的英夫利西单抗初治类风湿关节炎患者。
- 程序化组前6周接受3 mg/kg英夫利西单抗,14周后依据基线血清TNF-α水平调整剂量至第54周;标准组接受3 mg/kg英夫利西单抗。
- 第54周达到SDAI≤3.3者停用英夫利西单抗,主要终点为第106周持续停药的患者比例。
主要发现
- 第54周程序化组39.4%(67/170)与标准组32.3%(54/167)达到SDAI≤3.3缓解。
- 第106周持续停药率程序化组23.5%(40/170)、标准组21.6%(36/167),差异2.2%(95%CI -6.6%至11.0%;p=0.631)。
- 基线SDAI<26.0为第106周成功持续停药的显著预测因素。
关键数值与推荐
- 第54周以SDAI≤3.3定义缓解并作为停药条件。
- 主要终点为第106周持续停用英夫利西单抗的患者比例。
临床怎么用
- 对甲氨蝶呤应答不足的类风湿关节炎患者,程序化按基线TNF-α调整英夫利西单抗剂量未显示提高持续停药率的优势。
- 基线SDAI<26.0或可辅助识别第106周成功持续停药可能性更高的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The aim of this study is to determine whether the 'programmed' infliximab (IFX) treatment strategy (for which the dose of IFX was adjusted based on the baseline serum tumour necrosis factor α (TNF-α)) is beneficial to induction of clinical remission after 54 weeks and sustained discontinuation of IFX for 1 year. METHODS: In this multicentre randomised trial, patients with IFX-naïve rheumatoid arthritis with inadequate response to methotrexate were randomised to two groups; patients in programmed treatment group received 3 mg/kg IFX until week 6 and after 14 weeks the dose of IFX was adjusted based on the baseline levels of serum TNF-α until week 54; patients in the standard treatment group received 3 mg/kg of IFX. Patients who achieved a simplified disease activity index (SDAI) ≤3.3 at week 54 discontinued IFX. The primary endpoint was the proportion of patients who sustained discontinuation of IFX at week 106. RESULTS: A total of 337 patients were randomised. At week 54, 39.4% (67/170) in the programmed group and 32.3% (54/167) in the standard group attained remission (SDAI ≤3.3). At week 106, the 1-year sustained discontinuation rate was not significantly different between two groups; the programmed group 23.5% (40/170) and the standard group 21.6% (36/167), respectively (2.2% difference, 95% CI -6.6% to 11.0%; p=0.631). Baseline SDAI <26.0 was a statistically significant predictor of the successfully sustained discontinuation of IFX at week 106. CONCLUSION: Programmed treatment strategy did not statistically increase the sustained remission rate after 1 year discontinuation of IFX treatment.
引用
- Tanaka Y, Oba K, Koike T, et al. Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial. Ann Rheum Dis. 2019. PMID: 31630117. doi:10.1136/annrheumdis-2019-216169
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。